Array reports less revenue, greater loss
Last Updated: 15:08 April 29, 2014
The revenue marked a drop of 22 percent from $10 million for the same period a year ago for the Boulder-based firm. The net loss was greater than the same period a year ago, which was $21.6 million. It amounted to 20 cents per share compared with 19 cents per share for the third quarter last year.
Array develops research drug candidates used to treat cancer patients.
The company attributed the decreased revenue to a reduction in license and milestone payments from its original Celgene collaboration that ended last year.
"We are encouraged to see six ASCO abstracts reporting clinical data for our two partnered MEK programs, while steady progress continues across the six pivotal trials for these programs," Array chief executive Ron Squarer said in a press release. "Internally, we remain focused on advancing filanesib, which has the potential to be an important novel mechanism for treating patients with multiple myeloma."
Array shares were trading at $4.02 by late afternoon Tuesday, a 6.1 percent increase from the previous day's close.
More breaking news...
Level 3 wins U.S. Homeland Security contract
As part of the agreement, SNC will
DigitalGlobe’s satellites help watch forest fires
Startup's app helps students discover events
Varsity co-founders Devon Tivona and Lianne